Cellworks Research India Private Limited products

The Cellworks Platform biosimulates how a patient’s unique cancer will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients. Therapy biosimulation is the ability to predict the phenotype response of a human cell to an external stimulus, such as a drug ligand or radiation. We utilize this technology, to determine a patient’s Therapy Response Index, or TRI. A treatment-naïve patient’s TRI determines whether the patient will respond to standard care treatment. For relapsed or refractory patients, TRI determines the ideal combination of FDA approved drugs to which the patient will respond.